Cabaletta Bio receives FDA fast track designation for DSG3-CAART for the treatment of mucosal pemphigus vulgaris

6 May 2020 - Cabaletta Bio today announced that the U.S. FDA has granted fast track designation for DSG3-CAART (Desmoglein 3 ...

Read more →

GeneTx and Ultragenyx announce GTX-102 granted fast track designation by US FDA for treatment of Angelman syndrome

4 May 2020 - GeneTx Biotherapeutics and Ultragenyx today announced that the U.S. FDA has granted fast track designation to GTX-102 ...

Read more →

FDA grants Carmell Therapeutics expedited review for CT-101, bone healing accelerant

27 April 2020 - Carmell to begin enrolling in pivotal clinical program for first-of-its-kind plasma-based bioactive material product used in long-bone ...

Read more →

Erytech Pharma granted U.S. FDA fast track designation for eryaspase in second-line pancreatic cancer

28 April 2020 - Fast track designation for eryaspase underscores the urgent need for potential new treatment options for patients with ...

Read more →

A new FDA fast track designation for Zambon

28 April 2020 - The designation is for L‑CsA‑i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a ...

Read more →

Wockhardt receives US FDA qualified infectious disease product designation for WCK 6777, a first ever once-a-day β-lactam enhancer class antibiotic

20 April 2020 -  WCK 6777 is a once-a-day combination antibiotic based on Wockhardt’s NCE zidebactam, which imparts WCK 6777 ...

Read more →

Chi-Med announces surufatinib granted U.S. FDA fast track designations for the treatment of both pancreatic and non-pancreatic neuroendocrine tumours

17 April 2020 - Hutchison China MediTech today announces that the U.S. FDA has granted two fast track designations for the ...

Read more →

FDA grants fast track designation to RemeGen's telitacicept as a treatment for systemic lupus erythematosus

15 April 2020 - RemeGen today announced that the US FDA granted fast track designation for RC18, a novel recombinant TACI-Fc ...

Read more →

LifeMax receives fast track designation for LM-030 for the treatment of Netherton syndrome

14 April 2020 - LifeMax Laboratories today announced that the FDA granted fast track designation to LM-030, an investigational therapy licensed ...

Read more →

Alnylam receives fast track designation for vutrisiran for the treatment of the polyneuropathy of hATTR amyloidosis

14 April 2020 - Alnylam Pharmaceuticals announced today that the U.S. FDA has granted fast track designation to vutrisiran, an ...

Read more →

EicOsis EC5026 granted fast track designation by FDA for neuropathic pain

9 April 2020 - EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of ...

Read more →

Agenus receives fast track designation for balstilimab in advanced cervical cancer

7 April 2020 - Agenus today announced that the U.S. FDA has granted Agenus fast track designation for investigation of balstilimab ...

Read more →

FDA grants fast track designation to sacituzumab govitecan for urothelial cancer

7 April 2020 - Immunomedics today announced that the U.S. FDA has granted fast track designation for sacituzumab govitecan for the ...

Read more →

Blaze Bioscience announces FDA has granted fast track designation to BLZ-100 (tozuleristide) for paediatric central nervous system tumours

7 April 2020 - Phase 2/3 pivotal trial ongoing in patients up to 30 years of age undergoing surgery for paediatric ...

Read more →

IVERIC bio announces fast track designation from U.S. FDA for Zimura for the treatment of geographic atrophy secondary to dry age-related macular degeneration

3 April 2020 - IVERIC bio announced today that the U.S. FDA has granted fast track designation to Zimura (avacincaptad ...

Read more →